Deutsche Märkte schließen in 7 Stunden 2 Minuten

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
0,6466+0,0367 (+6,02%)
Börsenschluss: 04:00PM EDT
0,6730 +0,03 (+4,08%)
Vorbörslich: 05:19AM EDT

Veru Inc.

2916 North Miami Avenue
Suite 1000
Miami, FL 33127
United States
305 509 6897
https://verupharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter189

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Mitchell S. Steiner F.A.C.S., M.D.Chairman, President & CEO885,32kN/A1961
Dr. Harry Fisch F.A.C.S., M.D.Vice Chairman & Chief Corporate OfficerN/AN/A1959
Ms. Michele GrecoCFO & Chief Administrative Officer493,7kN/A1959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer676,27kN/A1968
Mr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryN/AN/AN/A
Mr. Kevin J. Gilbert CPA, J.D.Executive Vice President of Corporate DevelopmentN/AN/AN/A
Mr. Martin TaylerExecutive Vice President of FC2 Global Operations180,51kN/A1969
Mr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselN/AN/AN/A
Dr. Domingo Rodriguez M.D.Executive Vice President of Global Clinical OperationsN/AN/A1962
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Corporate Governance

Veru Inc.s ISS Governance QualityScore, Stand 1. März 2024, lautet 9. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 4, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.